Cell Therapy Catapult Launches New CAR-T Company Targeting Solid Tumors
This article was originally published in Scrip
Executive Summary
The Cell Therapy Catapult (CTC), a UK-based organization focused on growth of the UK cell and gene therapy sector, is teaming up with the University of Birmingham and Cancer Research UK to develop a new generation chimeric antigen receptor T-Cell (CAR-T) immune-oncology therapy for solid tumors.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.